Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by mjn797979on Jul 08, 2020 3:42pm
44 Views
Post# 31241355

RE:GUD thoughts:

RE:GUD thoughts:I don't see it mentioned to be done in 16 days.

From their Q1 report I am pasting this:

"November 29, 2019 the Company acquired a controlling stake of 51.2% in GBT (“GBT Transaction”), from a controlling 
shareholder group that included Advent International and Essex Woodlands, among others. The purchase price per share 
paid by the Company at closing was $3.48 [BRL 10.96], for an aggregate purchase price of $189,024 [BRL 595,662], which 
was funded entirely from the Company’s cash on hand. An amount equivalent to 20% of the Purchase Price was deposited 
in escrow to secure the sellers' indemnification obligations under the purchase agreement for the GBT Transaction. The 
escrow amount will be released equally over a period of three years from closing, net of claims in accordance with the terms 
and conditions of the Share Purchase Agreement.
The remaining 48.8% ownership of GBT is publicly-held and traded on B3, Brazil’s main stock exchange, through BDRs. 
Following the close of the GBT Transaction, Knight initiated the process of launching a mandatory public tender offer to 
acquire the BDRs from public shareholders (the "Unified Tender Offer") on similar terms as the GBT Transaction plus interest 
at the Selic rate calculated from November 29, 2019 until the settlement date. Alternatively, the public shareholders’ may 
opt to be paid in cash on the settlement date an amount of BRL10.15 per BDR plus interest at the Selic rate calculated from 
November 29, 2019. On December 20, 2019, the Company submitted to B3 an authorization request to carry out the Unified 
Tender Offer, which is expected to take up to 9 months from launch to completion."

This would take us to September for the tender offer.
I recall Samira mention 4 to 8 months in the Q4 results but now in Q1 I see this.




 
Bullboard Posts